A Custom ALS Drug Took Three Years to Build and One Year to Normalise One Man’s Neurofilament
Built in about three years for one mutation, it normalised a biomarker in one man. A larger cohort sits outside the paper.
Month: September 2026
UnitedHealthcare Is Enlisting Doctors Against the Paperwork Behind 43% of Projected Medicaid Losses
CMS expects much of the coverage loss to come from process, not from failing the test. The insurer asked doctors to help.
China Ordered Rare Disease Clinics in Every Province by December and Left Payment Out
Every instruction raises the number of diagnosed patients. None addresses what they can be prescribed, or who pays.
Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
Telix Is Paying $1.65 Billion for ITM Without Handing the Sellers Any Cash at Closing
The sellers receive shares, not cash, at closing, and $450m of the $700m earnout rests on a single year of sales.
India Got Three Different Access Mechanisms in Four Days
Three routes to patients in four days. In a market that pays out of pocket, not one announcement carries a price.
Japan Clears Five Products in a Day, Two With a Price Cut Attached
Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.
The CHMP Refused Nothing in September and Five Applications Were Pulled Anyway
Twelve approvals and no refusals. Apitegromab was cleared in the US on 11 September and pulled in Europe by the 17th.
Lilly’s New Combination Beats its Own Monotherapy
Median PFS doubled to 11.1 months against Inluriyo alone. The comparison payers will run is not in the package.
GENEROUS Signings Jump From Seven to 40 States in a Week
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.